These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27743776)

  • 1. An FDA oncology analysis of immune activating products and first-in-human dose selection.
    Saber H; Gudi R; Manning M; Wearne E; Leighton JK
    Regul Toxicol Pharmacol; 2016 Nov; 81():448-456. PubMed ID: 27743776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection.
    Saber H; Del Valle P; Ricks TK; Leighton JK
    Regul Toxicol Pharmacol; 2017 Nov; 90():144-152. PubMed ID: 28887049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An FDA oncology analysis of antibody-drug conjugates.
    Saber H; Leighton JK
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):444-52. PubMed ID: 25661711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.
    Hansen AR; Cook N; Ricci MS; Razak A; Le Tourneau C; McKeever K; Roskos L; Dixit R; Siu LL; Hinrichs MJ
    Oncologist; 2015 Jun; 20(6):653-9. PubMed ID: 25964306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach.
    Schaller TH; Snyder DJ; Spasojevic I; Gedeon PC; Sanchez-Perez L; Sampson JH
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
    Muller PY; Milton M; Lloyd P; Sims J; Brennan FR
    Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013.
    Suh HY; Peck CC; Yu KS; Lee H
    Drug Des Devel Ther; 2016; 10():4005-4016. PubMed ID: 27994442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates.
    Saber H; Simpson N; Ricks TK; Leighton JK
    Regul Toxicol Pharmacol; 2019 Oct; 107():104429. PubMed ID: 31325532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment.
    Leach MW; Clarke DO; Dudal S; Han C; Li C; Yang Z; Brennan FR; Bailey WJ; Chen Y; Deslandes A; Loberg LI; Mayawala K; Rogge MC; Todd M; Chemuturi NV
    Clin Pharmacol Ther; 2021 Jun; 109(6):1395-1415. PubMed ID: 32757299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A brief survey of first-in-human studies.
    Wexler D; Bertelsen KM
    J Clin Pharmacol; 2011 Jul; 51(7):988-93. PubMed ID: 20671293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
    Muller PY; Brennan FR
    Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
    Delnomdedieu M; Duvvuri S; Li DJ; Atassi N; Lu M; Brashear HR; Liu E; Ness S; Kupiec JW
    Alzheimers Res Ther; 2016 Mar; 8(1):12. PubMed ID: 26925577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-informed drug development for immuno-oncology agonistic anti-GITR antibody GWN323: Dose selection based on MABEL and biologically active dose.
    Ji Y; Knee D; Chen X; Dang A; Mataraza J; Wolf B; Sy SKB
    Clin Transl Sci; 2022 Sep; 15(9):2218-2229. PubMed ID: 35731955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals.
    Tibbitts J; Cavagnaro JA; Haller CA; Marafino B; Andrews PA; Sullivan JT
    Regul Toxicol Pharmacol; 2010 Nov; 58(2):243-51. PubMed ID: 20558225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clearance as an Early Indicator of Efficacy for Therapeutic Monoclonal Antibodies: Circumventing Dose Selection Challenges in Oncology.
    Chen C; Fan X; Zhang L; Xu P; Zou H; Zhao X; Gupta M; Feng YS; Xu XS; Yan X
    Clin Pharmacokinet; 2023 May; 62(5):705-713. PubMed ID: 36930421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.
    Tosi D; Laghzali Y; Vinches M; Alexandre M; Homicsko K; Fasolo A; Del Conte G; Durigova A; Hayaoui N; Gourgou S; Gianni L; Mollevi C
    J Clin Oncol; 2015 Jul; 33(19):2158-65. PubMed ID: 26014300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hazard identification and risk assessment for biologics targeting the immune system.
    Weir AB
    J Immunotoxicol; 2008 Jan; 5(1):3-10. PubMed ID: 18382852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
    Viala M; Vinches M; Alexandre M; Mollevi C; Durigova A; Hayaoui N; Homicsko K; Cuenant A; Gongora C; Gianni L; Tosi D
    Br J Cancer; 2018 Mar; 118(5):679-697. PubMed ID: 29438365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.
    Brennan FR; Andrews L; Arulanandam AR; Blumel J; Fikes J; Grimaldi C; Lansita J; Loberg LI; MacLachlan T; Milton M; Parker S; Tibbitts J; Wolf J; Allamneni KP
    Regul Toxicol Pharmacol; 2018 Oct; 98():98-107. PubMed ID: 30026135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.